



# **Correlation Between Serum Level Of Immunoglobulin And Antiepileptic Drugs In Sample Of Egyptian Epileptic Patients**

*Thesis*

*Submitted for partial fulfillment of Master degree in science of  
Neurology and Psychiatry*

Presented by

**Ihssan Yasin Mohamed Mohamed**

*(M.B., B.Ch)*

Supervised by

**Prof. Dr. Yousry Aboelnaga Abdelhamied**

*Professor of Neurology*

*Faculty of Medicine, Ain Shams University*

**Dr. Ahmed Mohamed Hazzou**

*Assistant Professor of Neurology*

*Faculty of Medicine, Ain Shams University*

**Dr. Mona Mokthar Wahideldin**

*Lecturer of Neurology*

*Faculty of Medicine, Ain Shams University*

**Faculty of Medicine**

**Ain Shams University**

**2019**



## **العلاقة بين مستوى الأجسام المناعية في الدم و الادوية المضادة للصرع □ في عينة من مرضى الصرع المصريين**

رسالة

توطئة للحصول علي درجة الماجستير في طب المخ والاعصاب و

الطب النفسي

مقدمة من

الطبيبة/إحسان ياسين محمد محمد

بكالوريوس الطب و الجراحة

تحت إشراف

□ أ.د/يسري أبو النجا عبد الحميد

أستاذ طب المخ والاعصاب

كلية الطب- جامعة عين شمس

□ د/ أحمد محمد عبد القادر حظو

أستاذ مساعد طب المخ والاعصاب

كلية الطب- جامعة عين شمس

د/ منى مختار وحيد الدين

مدرس طب المخ والاعصاب

كلية الطب- جامعة عين شمس

كلية الطب

جامعة عين شمس

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

لَسْبَحَانَكَ لَا عِلْمَ لَنَا  
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ  
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢



# Acknowledgement

*First and foremost thanks to **ALLAH**, the Most Merciful.*

*I would like to express my deepest appreciation and gratitude to **Prof. Dr. Yousry Aboelnaga Abdalhamid**, Professor of Neurology, Faculty of Medicine \_Ain Shams University and to **Dr. Ahmed Mohamed Hazzou**, Professor of Neurology, Faculty of Medicine\_Ain Shams University, for helping me choosing this important and up-to-date topic, and for their continuous and unconditioned guidance and support.*

*I would also like to thank also **Dr. Mona Mokhtar Wahideldin**, lecturer of Neurology, Faculty of Medicine\_Ain Shams University, for her patience and meticulous remarks which have helped me keep this essay structured, organized and concise.*

*Thanks to my friends and colleagues in the Neurology Department of Ain Shams University, for helping me in many ways through out my training.*

*Last but not least, I thank my family, especially my daughters Nancy & Talia and my husband for being there for me along the road, and for whom I owe everything I am, and will ever be.*

## **CONTENTS**

<b>Subjects</b>	<b>Page</b>
• List of Abbreviation .....	I
• List of table .....	III
• List of Figures .....	V
• Introduction .....	1
• Aim of the Work.....	4
• Review of literature: .....	
Chapter 1:Innate and Adaptive immunity in human epilepsies.....	5
Chapter 2:Inflammatory pathway of seizures.....	16
Chapter 3:Antiepileptic drugs and immune system.....	24
• Subjects And Methods.....	35
• Results.....	39
• Discussion.....	51
• Summary And Conclusion .....	56
• Recommendations .....	59
• References .....	61
• Appendix .....	70
• Arabic Summary .....	

---

## LIST OF ABBREVIATION

<b>ACTH</b>	: Adrenocorticotrophic hormone
<b>AMPA</b>	: Amino-3-hydroxy-5-methyl-4-isoxazole propionic acid
<b>AED</b>	: Antiepileptic drugs
<b>AHS</b>	: Antiepileptic hypersensitivity syndrome
<b>ANABs</b>	: Antineuronal autoantibodies
<b>AUC</b>	: Area under the curve
<b>BBB</b>	: Blood brain barrier
<b>BBBD</b>	: Blood brain barrier disruption
<b>CBZ</b>	: carbamazepine
<b>CNS</b>	: Central nervous system
<b>CSF</b>	: Cerebrospinal fluid
<b>CXCL12</b>	: Chemokine receptor
<b>CXCLR4</b>	: Chemokine receptor
<b>CCL2</b>	: Chemokine receptor
<b>CCR2</b>	: Chemokine receptor
<b>CVID</b>	: Common variable immunodeficiency
<b>CFS</b>	: Complex febrile seizure
<b>Caspr2</b>	: Contactin-associated protein-like 2
<b>COX-2</b>	: cyclooxygenase
<b>CYP</b>	: Cytochrome P
<b>CYP3A4</b>	: Cytochrome P450 3A4
<b>DHS</b>	: Drug hypersensitivity syndrome
<b>DRESS</b>	: Drug rash with eosinophilia and systemic symptoms
<b>FCD</b>	: Focal cortical dysplasia
<b>GTCs</b>	: Generalized tonic clonic seizure
<b>HHV-6</b>	: High human herpes virus -6
<b>HMGB 1</b>	: High mobility group box 1
<b>HS</b>	: Hippocampal sclerosis
<b>Hu</b>	: Hu intracellular tumor antigen
<b>HPA</b>	: Hypothalamic-pituitary-adrenal
<b>IHC</b>	: Immune histochemical
<b>IG</b>	: immunoglobulin
<b>ISH</b>	: In situ hybridization
<b>IFN</b>	: Interferon
<b>IL</b>	: interleukin
<b>IL-1RA</b>	: Interleukin 1 receptor antagonist
<b>IL-1b</b>	: Interleukin-1b
<b>IL-6</b>	: Interleukin-6
<b>ILAE</b>	: International league against Epilepsy

---

---

## *List of Abbreviation*

---

<b>IVIG</b>	: Intravenous immunoglobulin
<b>LEMS</b>	: Lambert-Eaton myasthenic syndrome
<b>LTG</b>	: lamotrigine
<b>LGI1</b>	: Leucine-rich glioma- inactivated 1
<b>LEV</b>	: levetiracetam
<b>LPS</b>	: lipopolysaccharides
<b>LE</b>	: Lupus erythematosus
<b>Ma2</b>	: Ma2 intracellular tumor antigen
<b>MTS</b>	: Mesial temporal sclerosis
<b>mRNA</b>	: Messenger RNA
<b>ADAM22</b>	: Metalloproteinase domain-containing protein 22
<b>MS</b>	: Multiple sclerosis
<b>NK</b>	: Natural killer
<b>NMDAR</b>	: N-methyl-D-aspartate receptor
<b>NF-KB</b>	: Nuclear factor kappa-light-chain-enhancer of activated Bcells
<b>PCR</b>	: Polymerase chain reaction
<b>PERM</b>	: Progressive encephalomyelitis with rigidity and myoclonus
<b>RE</b>	: Rasmussen encephalitis
<b>SE</b>	: Status epilepticus
<b>SPS</b>	: Stiff-person syndrome
<b>SAM</b>	: Sympathetic-adrenal-medullary
<b>TLE</b>	: Temporal lobe epilepsy
<b>TLRs</b>	: Toll-like receptors
<b>TGF</b>	: Transforming growth factor
<b>TNF-a</b>	: Tumor necrosis factor-a
<b>VNS</b>	: Vagus nerve stimulation
<b>VPA</b>	: Valproic acid
<b>VEGF</b>	: Vascular endothelial growth factor
<b>VGKC</b>	: Voltage-gated potassium channel

## LIST OF TABLE

<b>Tab. No.</b>	<b>Subject</b>	<b>Page</b>
<b>Table(1)</b>	Reference values of serum level of IgG, IgA and IgM	37
<b>Table(2)</b>	Comparison between all groups as regard age and gender	41
<b>Table(3)</b>	Comparison between patient's groups as regard duration of epilepsy, EEG findings and MRI brain findings	42
<b>Table(4)</b>	Comparison between carbamazepine, carbamazepine and levetiracetam groups as regard serum level of IgG and IgA	44
<b>Table(5)</b>	Relation between duration of antiepileptic drugs intake and serum level of immunoglobulin	47
<b>Table(6)</b>	Relation between time of last seizure and serum level of immunoglobulin	48
<b>Table(7)</b>	Relation between semiology of seizure and serum level of immunoglobulin	49
<b>Table(8)</b>	Relation between MRI brain findings and serum level of immunoglobulin	50



## LIST OF FIGURES

<i>Fig. No.</i>	<i>Subject</i>	<i>Page</i>
<b>Fig. (1)</b>	Comparison between all groups as regard serum level of IgG	43
<b>Fig. (2)</b>	Comparison between all groups as regard serum level of IgA and IgM	43
<b>Fig (3)</b>	Comparison between carbamazepine, carbamazepine and valporate, carbamazepine and levetiracetam groups as regard serum level of IgG	45
<b>Fig(4)</b>	Comparison between carbamazepine, carbamazepine and valporate, carbamazepine and levetiracetam groups as regard serum level of IgA and IgM	46

### **Abstract**

**Background:** Data on the effects of antiepileptic drugs on immune system are frequently inconsistent and some time conflicting because the affects of drugs cannot be separated from those of seizures, first-generation drugs have been most intensively investigated, the genetic background of the patients, the mechanism of action and pharmacokinetics profile of the AEDs may act as confounders. Valproate, carbamazepine, phenytoin, vigabtrin, levetiracetam and diazepam have been found to modulate the immune system activities by affecting humoral and cellular immunity.

**Aim of work:** To investigate serum immunoglobulin IgG, IgA and IgG concentrations in patients with focal epilepsy, shortly after first presentation of one or more unprovoked epileptic seizures before the start the treatment with AEDs, and compared them with patients treated with three different antiepileptic drugs carbamazepine (CBZ), Sodium valproate (VPA) and Levetiracetam (LEV) in monotherapy and in polytherapy, for at least three months of drug intake duration.

**Patients and Methods:** This cross sectional descriptive study conducted in the epilepsy clinic, department of Neurology, Ain Shams University. This present study aimed at describing data of 82 patients with focal epilepsy based on clinical course, EEG report and MRI brain images who attended the epilepsy clinic over a year period from, February 2018 to February 2019. Plasme Immunoglobulin levels were measured with quantitative methods using a Biosystems kits and is presented as mg/dL. **Results:** A total 82 subjects in the age range of 13-53 years old met the inclusion and exclusion criteria of this study. Serum level of IgG, IgA and IgM is not altered in patients shortly after the first presentation with epileptic seizures and before start treatment with antiepileptic drugs **Conculusion:** This study indicated that carbamazapine in monotherapy and in combination with valproate and levetiracetam decrease serum levels of Immunoglobulin in patients with focal epilepsy. However, humoral immunity was not altered in patients shortly after the first presentation with epileptic seizures and before the start the treatment with AEDs. Professionals who frequently prescribe these drugs should be alert to this alteration. Although in our study, patients with immunoglobulin deficiency were asymptomatic, assessment of serum immunoglobulin levels should be done at starting the administration of AEDs and in serial intervals afterward in epileptic patients. Recurrent seizures are a significant cause of morbidity, we conclude that intravenous immunoglobulin (IVIG) is a safe therapy and may have beneficial effects in intractable epilepsies. More studies should be carried out to support the efficacy of IVIG in the treatment of intractable epilepsy and to elucidate the pathogenesis and the effects of this therapy, ideal dosage and treatment schedules should be define

---

**Keywords:** antiepileptic drugs, humoral & cellular immunity, adverse effects, serum immunoglobulin, seizures, Focal epilepsy.

---

## INTRODUCTION

More than 50 million people worldwide have epilepsy, making it one of the most common neurological diseases globally. Nearly 80% of people with epilepsy living in low- and middle income countries (*Lancet, 2019*).

Antiepileptic drugs (AEDs) are the cornerstone in epilepsy treatment. When medication for epilepsy is introduced, it may have to be continued for many years, sometimes throughout life. Antiepileptic drugs are in a very common use not only for epilepsy, but also in psychiatry as mood stabilizers, for the treatment of neuropathic pain, and for migraine prophylaxis. Increasing of evidence indicated that beside the central nervous system, antiepileptic drugs may also affect the immune system. Experimental data showed that classical and newer antiepileptic drugs affect peripheral immunological parameters (*Patsalos& Bourgeois, 2010*).

Data on the effects of antiepileptic drugs on the immune system are frequently inconsistent and sometimes conflicting because the effects of drugs cannot be separated from those of seizures, first generation drugs have been most intensively investigated than the new compounds, which may explain their predominant involvement in immune mediated reactions. The patient's genetic background, the mechanism of action and the pharmacokinetic profile of AEDs and the concurrent use of

immunosuppressant drugs may act as confounders. Valproate, carbamazepine and levetiracetam have been found to modulate the immune system activity by affecting humoral and cellular immunity (*Aarli, 2010*).

Carbamazepine (CBZ) was the first AEDs assumed to have an effect on the immune system. It has been associated with immune dysfunction with subnormal concentrations of all immunoglobulin. In a study started in 2013, patients were followed up after the administration of carbamazepine, a significant reduction in IgG and IgA was found (*Svalheim et al., 2013*).

Levetiracetam (LEV) has been also associated with reversible immunoglobulin deficiency. Involvement of the immune system has been studied since the drug was first used, and accordingly affects as many as 47% of the levetiracetam treated-patients. Among the changes described are IgA and IgM deficiency (*Svalheim et al., 2013*). Decreased serum IgG levels have been reported in a few studies and in isolated clinical cases (*Kim et al., 2010*).

There are also a few reports suggesting that sodium valproate (VPA) may induce low levels of IgA, IgG, and IgM, where the diagnosis of common variable immunodeficiency (CVID) has been reported. Several cases of hypogammaglobulinemia, with a phenotype similar to CVID in sodium valproate-treated patients have

been noted. This observation is interesting because sodium valproate is frequently prescribed (*Vazzani, 2011*).

Low levels of immunoglobulin as occur in some patients following the administration of antiepileptic drugs are associated with significantly increased risks of infections, primarily respiratory tract infections of bacterial origin. Patients with IgG level below 100 mg/ dl or IgM below 20 mg/dl for prolonged period have an increased risk of recurrent and sometimes life-threatening infectious episodes. Generally, IgA deficiency appears to be better tolerated. Replenishment of IgG in patients with hypogammaglobulinemia reduces the infection risk to background if IgG levels are maintained at approximately 500 mg/dl, although higher levels may be necessary in the presences of comorbidities (*Holmes, 2013*)

Immune system dysfunction may play role in triggering or maintaining intractable seizure. Some investigators have suggested that intractable seizure unresponsive to antiepileptic drugs may reflect occult immunoglobulin deficiency. In a previous trial study; it was found that intractable seizures have been associated with IgG subclasses deficiency. Consequently, these patients received intravenous immunoglobulin. A marked reduction in the frequency of seizures to almost complete disappearance was observed (*Shovron, 2010*).

## **AIM OF THE WORK**

We aimed to verify serum concentration of immunoglobulin; IgG, IgA and IgM in patients with focal epilepsy treated with three different antiepileptic drugs carbamazepine (CBZ), Sodium valproate (VPA) and Levetiracetam (LEV) as monotherapy and as polytherapy.

## **INNATE AND ADAPTIVE IMMUNITY IN HUMAN EPILEPSIES**

Immune mechanisms have been discovered in several neurologic diseases, some of them associated with epilepsy. These mechanisms are not only present in epilepsies caused by infectious and central nervous system inflammatory diseases (*Vezzani et al., 2016*) but also in epileptic disorders not associated with a clear inflammatory pathophysiology. The exact role of the inflammatory phenomena (cause, effect, or both) is a matter of intense investigation. Rapid activation of pro-inflammatory cytokines and danger signals is observed after acute epileptogenic brain injuries or after single and recurrent seizures in both experimental and clinical settings (*Walker et al., 2016*).

### **Innate Immunity in Epileptic Disorders**

There is evidence supporting that several inflammatory mediators have a specific role in temporal lobe epilepsy (TLE) or in neocortical epilepsies associated with focal malformations. Rapid activation of pro-inflammatory cytokines, such as interleukin-1b (IL-1b), interleukin-6(IL-6), and tumor necrosis factor-a (TNF-a), is observed after acute and chronic seizures in animal models of acquired epilepsies (*Iori et al., 2016*).